

Rostoff P, Zabczyk M, Natowska J, et al. Enhanced complement consumption and histone H3 citrullination predict disease severity and early mortality risk in non-high-risk pulmonary embolism. Pol Heart J. 2024.

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Correlation coefficients (Spearman's rho) of the C3a-to-C3 ratio and citrullinated histone H3 with disease severity, early mortality risk and parameters of the prothrombotic state and inflammation in the study patients

Parameter	Correlation with the C3a-to-C3 ratio		Correlation with H3Cit (ng/mL)	
	r	p	r	p
Parameters of disease severity and early mortality risk				
sPESI	0.34	<0.001	0.33	<0.001
NT-proBNP (pg/mL)	0.22	0.020	0.29	0.002
Parameters of the prothrombotic state				
Factor VIII (%)	0.26	0.007	0.12	0.231
ETP (nM*min)	0.18	0.063	0.29	0.002
CLT (min)	0.28	0.003	0.55	<0.001
K _s (10 ⁻⁹ cm ²)	- 0.24	0.011	- 0.11	0.238
TAFI (%)	- 0.21	0.032	0.01	0.917
PAI-1 (ng/mL)	0.12	0.213	0.44	<0.001
Parameters of inflammation				

White blood cells (10⁹/L)	0.25	0.009	0.04	0.660
Neutrophils (10⁹/L)	0.30	0.002	0.01	0.948
hsCRP (mg/L)	0.28	0.003	0.02	0.847
Interleukin-6 (pg/mL)	0.26	0.011	0.05	0.662

Abbreviations: CLT – clot lysis time, CRP – C-reactive protein, ETP – endogenous thrombin potential, H3Cit – citrullinated histone H3, hs – high-sensitivity, K_s – permeation coefficient, NT-proBNP – N-terminal pro-B-type natriuretic peptide, PAI-1 – plasminogen activator inhibitor-1, RV – right ventricular, sPESI – simplified pulmonary embolism severity index, TAFI – thrombin-activatable fibrinolysis inhibitor

Table S2. Predictors of the C3a-to-C3 ratio >0.21 and citrullinated histone H3 >3.1 ng/mL in the study patients*

Parameter	C3a-to-C3 ratio > 0.21 and H3Cit > 3.1 ng/mL							
	Unadjusted		Age-adjusted		Age- and sex-adjusted		Sex - and CKD-adjusted	
	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
NT-proBNP >300 pg/mL	3.65 (1.40-9.51)	0.008	3.49 (1.33-9.14)	0.011	3.49 (1.33-9.16)	0.011	3.86 (1.45-10.30)	0.007
NT-proBNP >600 pg/mL	2.78 (1.16-6.65)	0.022	2.58 (1.05-6.30)	0.038	2.57 (1.05-6.29)	0.038	2.82 (1.17-6.82)	0.022
Intermediate-high risk APE	2.65 (1.04-6.76)	0.042	2.37 (0.87-6.44)	0.091	2.36 (0.86-6.46)	0.095	2.66 (1.02-6.90)	0.045
sPESI	2.21 (1.31-3.72)	0.003	2.13 (1.25-3.63)	0.005	2.14 (1.25-3.66)	0.005	2.25 (1.32-3.85)	0.003
PAI-1, ng/mL	1.05 (1.01-1.09)	0.009	1.05 (1.01-1.09)	0.009	1.05 (1.01-1.09)	0.009	1.05 (1.01-1.09)	0.008
CLT, min	1.03 (1.01-1.05)	0.002	1.03 (1.01-1.05)	0.004	1.03 (1.01-1.05)	0.004	1.03 (1.01-1.05)	0.002

* The cut-off values of H3Cit and the C3a-to-C3 ratio were determined by ROC curve analysis for sPESI ≥1

Abbreviations: APE – acute pulmonary embolism, CI – confidence interval, H3Cit – citrullinated histone H3, CKD – chronic kidney disease, CLT – clot lysis time, NT-proBNP – N-terminal pro-B-type natriuretic peptide, OR – odds ratio, PAI-1 – plasminogen activator inhibitor-1, sPESI – simplified pulmonary embolism severity index

Table S3. Diagnostic value of the C3a-to-C3 ratio >0.21 and citrullinated histone H3 >3.1 ng/mL in the study patients*

Diagnostic value	C3a-to-C3 ratio > 0.21 and H3Cit > 3.1 ng/mL	C3a-to-C3 ratio > 0.21	H3Cit > 3.1 ng/mL
Intermediate-high risk APE			
Sensitivity, %	42.3 (23.4-63.1)	76.9 (56.4-91.0)	61.5 (40.6-79.8)
Specificity, %	78.3 (67.9-86.6)	50.6 (39.4-61.8)	63.9 (52.6-74.1)
Accuracy, %	69.7 (60.2-78.2)	56.9 (47.1-66.3)	63.3 (53.5-72.3)
Positive predictive value, %	37.9 (25.0-52.9)	32.8 (26.5-39.8)	34.8 (26.0-44.7)
Negative predictive value, %	81.3 (75.4-86.0)	87.5 (77.1-93.6)	84.1 (76.1-89.9)
sPESI ≥ 1			
Sensitivity, %	31.2 (22.0-41.6)	64.5 (53.9-74.2)	49.5 (38.9-60.0)
Specificity, %	100.0 (79.4-100.0)	93.8 (69.8-99.8)	100.0 (79.4-100.0)
Accuracy, %	41.3 (31.9-51.1)	68.8 (59.2-77.3)	56.9 (47.1-66.3)
Positive predictive value, %	100.0 (88.1-100.0)	98.4 (89.9-99.8)	100.0 (92.3-100.0)
Negative predictive value, %	20.0 (17.9-22.3)	31.3 (25.2-38.1)	25.4 (21.8-29.4)
Right ventricular dilatation			
Sensitivity, %	37.5 (22.7-54.2)	72.5 (56.1-85.4)	50.0 (33.8-66.2)
Specificity, %	79.7 (68.3-88.4)	53.6 (41.2-65.7)	62.3 (49.8-73.7)
Accuracy, %	64.2 (54.5-73.2)	60.6 (50.7-69.8)	57.8 (48.0-67.2)
Positive predictive value, %	51.7 (36.7-66.5)	47.5 (39.8-55.5)	43.5 (33.3-54.3)
Negative predictive value, %	68.8 (62.7-74.2)	77.1 (66.0-85.4)	68.3 (60.0-75.5)

* The cut-off values of H3Cit and the C3a-to-C3 ratio were determined by ROC curve analysis for sPESI ≥1

Abbreviations: APE – acute pulmonary embolism, H3Cit – citrullinated histone H3, sPESI – simplified pulmonary embolism severity index